A novel low-cost plug-and-play multi-spectral LED based fluorometer, with application to chlorophyll detection.

In this paper a novel low-cost multi-spectral optical fluorometer is presented and evaluated. The device uses a range of LEDs in the blue and violet regions of the electromagnetic spectrum and a mini-spectrometer to detect the emitted fluorescence in the UV to IR spectrum region. Custom built electronics and software were designed to control the system and the components were housed in bespoke 3D printed parts. A number of known fluorophores were tested to determine the capabilities of the fluorometer. Application of the device is demonstrated for the detection of chlorophyll a (Chl a) from laboratory grown algae and from environmental samples while analytical performance is established using both in vivo and extracted Chl a fluorescence and by comparison with a benchtop fluorometer.

Sensors for Coastal and Ocean Monitoring.

In situ water monitoring sensors are critical to gain an understanding of ocean biochemistry and ecosystem health. They enable the collection of high-frequency data and capture ecosystem spatial and temporal changes, which in turn facilitate long-term global predictions. They are used as decision support tools in emergency situations and for risk mitigation, pollution source tracking, and regulatory monitoring. Advanced sensing platforms exist to support various monitoring needs together with state-of-the-art power and communication capabilities. To be fit-for-purpose, sensors must withstand the challenging marine environment and provide data at an acceptable cost. Significant technological advancements have catalyzed the development of new and improved sensors for coastal and oceanographic applications. Sensors are becoming smaller, smarter, more cost-effective, and increasingly specialized and diversified. This article, therefore, provides a review of the state-of-the art oceanographic and coastal sensors. Progress in sensor development is discussed in terms of performance and the key strategies used for achieving robustness, marine rating, cost reduction, and antifouling protection.

Establishment of an antifouling performance index derived from the assessment of biofouling on typical marine sensor materials.

Marine biofouling, known as the unwanted accumulation of living organisms on submerged surfaces, is one of the main factors affecting the operation, maintenance and data quality of water quality monitoring sensors. This can be a significant challenge for marine deployed infrastructure and sensors in water. When organisms attach to the mooring lines or other submerged surfaces of the sensor, they can interfere with the sensor's operation and accuracy. They can also add weight and drag to the mooring system, making it more difficult to maintain the desired position of the sensor. This increases the cost of ownership to the point where it becomes prohibitively expensive to maintain operational sensor networks and infrastructures. Furthermore, the analysis and quantification of biofouling is extremely complex as it is based on biochemical methods such as the analysis of pigments such as chlorophyll-a as a direct indicator of the biomass of photosynthetic organisms, dry weight, carbohydrate analysis and protein analysis among others. In this context, this study has developed a method to estimate biofouling quickly and accurately on different submerged materials used in the marine industry and specifically in sensor manufacturing like copper, titanium, fiberglass composite, different types of polyoxymethylene (POMC, POMH), polyethylene terephthalate glycol (PETG) and 316L-stainless steel. To do this, in situ images of fouling organisms were collected with a conventional camera and image processing algorithms and machine learning models trained were used to construct a biofouling growth model. The algorithms and models were implemented with Fiji-based Weka Segmentation software. A supervised clustering model was used to identify three types of fouling to quantify fouling on panels of different materials submerged in seawater over time. This method is easy, fast and cost-effective to classify biofouling in a more accessible and holistic way that could be useful for engineering applications.

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.

BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis. METHODS: In two identical, phase 3, double-blind, double-dummy trials (ULTIMATE I and II), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive intravenous ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72) and oral placebo or oral teriflunomide (14 mg once daily) and intravenous placebo. The primary end point was the annualized relapse rate. Secondary end points included the number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) by 96 weeks and worsening of disability. RESULTS: A total of 549 participants were enrolled in the ULTIMATE I trial, and 545 were enrolled in the ULTIMATE II trial; the median follow-up was 95 weeks. In the ULTIMATE I trial, the annualized relapse rate was 0.08 with ublituximab and 0.19 with teriflunomide (rate ratio, 0.41; 95% confidence interval [CI], 0.27 to 0.62; P<0.001); in the ULTIMATE II trial, the annualized relapse rate was 0.09 and 0.18, respectively (rate ratio, 0.51; 95% CI, 0.33 to 0.78; P = 0.002). The mean number of gadolinium-enhancing lesions was 0.02 in the ublituximab group and 0.49 in the teriflunomide group (rate ratio, 0.03; 95% CI, 0.02 to 0.06; P<0.001) in the ULTIMATE I trial and 0.01 and 0.25, respectively (rate ratio, 0.04; 95% CI, 0.02 to 0.06; P<0.001), in the ULTIMATE II trial. In the pooled analysis of the two trials, 5.2% of the participants in the ublituximab group and 5.9% in the teriflunomide group had worsening of disability at 12 weeks (hazard ratio, 0.84; 95% CI, 0.50 to 1.41; P = 0.51). Infusion-related reactions occurred in 47.7% of the participants in the ublituximab group. Serious infections occurred in 5.0% in the ublituximab group and in 2.9% in the teriflunomide group. CONCLUSIONS: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. Ublituximab was associated with infusion-related reactions. (Funded by TG Therapeutics; ULTIMATE I and II ClinicalTrials.gov numbers, NCT03277261 and NCT03277248.).

Functional Reach Test, Single-Leg Stance Test, and Tinetti Performance-Oriented Mobility Assessment for the Prediction of Falls in Older Adults: A Systematic Review.

OBJECTIVE: The authors sought to systematically review the existing literature on the falls-related diagnostic test properties of the Functional Reach Test (FRT), single-leg stance test (SLST), and Tinetti Performance-Oriented Mobility Assessment (POMA) in older adults across settings and patient populations. METHODS: The PubMed, EMBASE, and CINAHL databases were searched (inception-July 2020). Inclusion criteria were participants aged 60 years or more, prospectively recorded falls, and the reporting of falls-related predictive validity. Manuscripts not published in English were excluded. Methodological quality of reporting was assessed using the Tooth Scale. RESULTS: Of 1071 studies reviewed, 21 met the inclusion criteria (12 POMA, 8 FRT, 6 SLST). Seven studies (58.3%) used a modified version of the POMA, and 3 (37.5%) used a modified FRT. For the outcome of any fall, the respective ranges of sensitivity and specificity were 0.076 to 0.615 and 0.695 to 0.97 for the POMA, 0.27 to 0.70 and 0.52 to 0.83 for the modified POMA, 0.73 and 0.88 for the FRT, 0.47 to 0.682 and 0.59 to 0.788 for the modified FRT, and 0.51 and 0.61 for the SLST in community-dwelling older adults. For the SLST, the sensitivity and specificity for recurrent falls in the community-dwelling setting were 0.33 and 0.712, respectively. CONCLUSION: All the clinical tests of balance demonstrated an overall low diagnostic accuracy and a consistent inability to correctly identify fallers. None of these tests individually are able to predict future falls in older adults. Future research should develop a better understanding of the role that clinical tests of balance play in the comprehensive assessment of falls risk in older adults. IMPACT: Neither the FRT, SLST, nor POMA alone shows consistent evidence of being able to correctly identify fallers across fall types, settings, or older adult subpopulations. These clinical tests of balance cannot substitute a comprehensive falls risk assessment and thus should be incorporated in practice solely to identify and track balance impairment in older adults.

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

BACKGROUND: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mAbs. OBJECTIVE: The objective was to determine optimal dose, infusion time, and activity of ublituximab in relapsing multiple sclerosis. METHODS: This is a phase 2, placebo-controlled study. Patients received three ublituximab infusions (150 mg over 1-4 hours on day 1 and 450-600 mg over 1-3 hours on day 15 and week 24) in six dosing cohorts. The primary endpoint was B-cell depletion. RESULTS: In all cohorts (N = 48), median B-cell depletion was >99% by week 4, maintained at weeks 24 and 48. Most common adverse events (AEs) were infusion-related reactions (all grade 1-2), with no apparent increased incidence at shorter infusion times. There were no AE-related discontinuations. At weeks 24 and 48, no T1 gadolinium-enhancing lesions (p = 0.003) and a 10.6% decrease in T2 lesion volume (p = 0.002) were detected. The annualized relapse rate was 0.07; 93% remained relapse free on study. Overall, 74% of patients had no evidence of disease activity (NEDA). CONCLUSION: Ublituximab was safely infused as rapid as 1 hour, producing robust B-cell depletion and profound reductions in magnetic resonance imaging (MRI) activity and relapses.